Navigation Links
Cepheid Reports Fourth Quarter and Full Year 2011 Results

SUNNYVALE, Calif., Jan. 26, 2012 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2011 of $80.1 million.  Net loss was $1.6 million, or $(0.03) per share, which compares to revenue of $58.7 million and net income of $1.3 million, or $0.02 per diluted share, in the fourth quarter of 2010.  As anticipated, the fourth quarter net loss reflected a one-time, non-cash charge to cost of sales of $5.4 million, or $0.08 per share, associated with the termination of a patent license.

Excluding stock compensation expenses, the non-cash charge of $5.4 million associated with the termination of a patent license, and amortization of acquired intangibles, non-GAAP net income for the fourth quarter of 2011 was $9.4 million, or $0.14 per share.  This compares to a non-GAAP net income of $6.1 million, or $0.09 per share, in the fourth quarter of 2010.

Fiscal 2011 OverviewFor the year ended December 31, 2011, Cepheid reported revenue of $277.6 million which compares to revenue of $212.5 million in 2010.  Net income for the year was $2.6 million, or $0.04 per diluted share, which compares to a net loss of $5.9 million, or $(0.10) per share, in 2010.  Excluding stock compensation expenses, the non-cash charge of $5.4 million associated with the termination of a patent license, and amortization of acquired intangibles, non-GAAP net income for the year was $29.6 million, or $0.44 per share.  This compares to a non-GAAP net income of $12.5 million, or $0.20 per share, for the full year 2010.

"GeneXpert system placements continued at a very strong pace in the fourth quarter contributing to a record number of placements during 2011, in both our commercial and High Burden Developing Country programs," said John Bishop, Cepheid's Chief Executive Officer.  "The demand for our GeneXpert systems has continued to grow,684)(2,522)  Amortization of terminated patent license(5,372)-(5,372)-  Amortization of purchased intangible assets(347)(394)(1,383)(1,422)Non-GAAP measure of cost of product sales$
,191Gross margin on product sales per GAAP50%53%54%49%Gross margin on product sales per Non-GAAP58%55%57%51%Operating expenses$
5,871  Stock compensation expense(4,806)(3,614)(18,084)(14,093)  Amortization of purchased intangible assets(107)(78)(429)(409)Non-GAAP measure of operating expenses$
91,369Income (loss) from operations$
(5,344)  Stock compensation expense5,2494,30119,76816,615  Amortization of terminated patent license5,372-5,372-  Amortization of purchased intangible assets4544721,8121,831Non-GAAP measure of income from operations$
3,102Net income (loss)$
(5,917)  Stock compensation expense5,2494,30119,76816,615  Amortization of terminated patent license5,372-5,372-  Amortization of purchased intangible assets4544721,8121,831Non-GAAP measure of net income$
2,529Basic net income (loss) per share$
(0.10)  Stock compensation expense0.080.070.320.28  Amortization of terminated patent license0.09-0.08-  Amortization of purchased intangible assets0. measure of net income per share$
.21Diluted net income (loss) per share$
(0.10)  Stock compensation expense0.  Amortization of terminated patent license0.08-0.08-  Amortization of purchased intangible assets0. measure of net income per share$
.20Shares used in computing Non-GAAP basic net income (loss) per share64,11360,41362,73559,712Shares used in computing diluted net income per share64,11363,37266,75059,712Incremental shares from the assumed conversion of dilutive stock options4,4801,3678783,875Shares used in computing Non-GAAP diluted net income per share68,59364,73967,62863,587CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400 8377

Jacquie Ross

Cepheid Investor Relations

Tel: (408) 400 8329 in spite of continuing tight capital availability in the US and Europe.  In 2012, we will continue to invest aggressively in Xpert® test menu expansion to enable the benefits of our system to be realized in broader segments of the market. We expect to further extend our technology leadership and strong growth momentum in the quarters and years ahead."

Operational Overview

  • Fourth quarter of 2011 Clinical sales of $68.9 million grew 39% from $49.5 million in the fourth quarter of 2010, and total fourth quarter of 2011 product sales of $76.9 million grew 37% from the same quarter a year ago.  For the year ended December 31, 2011, total Clinical sales of $236.0 million grew 36% from $173.8 million reported for the same period a year ago.  
  • By industry, product sales were, in millions:

  • Three Months Ended December 31,Full Year Ended December 31,20112010Change20112010ChangeClinical Systems

    42.538%Clinical Reagents

    49.036.833%177.4131.335%Total Clinical 68.949.539%236.0173.836%Non-Clinical

    8.06.719%29.533.1-11%Total Product Sales$

  • By geography, product sales were, in millions:
  • Three Months Ended December 31,Full Year Ended December 31,20112010Change20112010ChangeNorth AmericaClinical


    7.25.433%25.027.3-8%Total North America53.643.922%192.9164.617%InternationalClinical


    0.81.3-38%4.55.8-22%Total International23.312.389%72.642.372%Total Product Sales$

  • During the fourth quarter of 2011, Cepheid placed a total of 175 GeneXpert systems in its commercial Clinical business.  Additionally, the Company placed a total of 181 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.  For the year ended December 31, 2011, Cepheid placed a total of 565 GeneXpert systems in its commercial Clinical business and an additional 418 GeneXpert systems as part of its HBDC program.  As of December 31, 2011, a cumulative total of 2,843 GeneXpert systems have been placed worldwide.
  • Cash and cash equivalents were $115.0 million as of December 31, 2011.
  • DSO was 40 days.

  • Business OutlookFor the fiscal year ending December 31, 2012, the Company expects:

  • Total revenue to be in the range of $333 to $347 million;
  • Net income in the range of $0.17 to $0.24 per share;  
  • Non-GAAP net income in the range of $0.55 to $0.60 per share.  

  • Expected non-GAAP net income excludes approximately $26 million related to stock compensation expense, approximately $2 million related to the amortization of acquired intangibles, and up to a $1.9 million non-cash tax benefit relating to a potential change to our international tax and legal entity structure.  The fully diluted share count for the year is expected to be between 70 and 71 million.

    Accessing Cepheid's Fourth Quarter and Full Year 2011 Results Conference CallThe Company will host a management presentation at 2:00 p.m. Pacific Time on Thursday, January 26, 2012, to discuss the results.  To access the live webcast, please visit Cepheid's website at at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

    Interested participants and investors may also listen to the live teleconference call by dialing (866) 713-8395 or (617) 597-5309, and entering participant code 42214013.  A replay will be available for seven days beginning at 4:00 p.m. Pacific Time.  Access numbers for this replay are (888) 286-8010 or (617) 801-6888, with passcode 57636855.

    About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the Company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the Company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit

    Use of Non-GAAP MeasuresThe Company has supplemented its reported GAAP financial information with non-GAAP measures that do not include employee share-based compensation expense, a non-cash charge associated with the termination of a patent license and amortization of purchased intangible assets.  The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with U.S. GAAP.   The Company's management uses the non-GAAP information internally to evaluate its ongoing business, continuing operational performance and cash requirements, and believes these non-GAAP measures are useful to investors as they provide a basis for evaluating the Company's cash requirements and additional insight into the underlying operating results and the Company's ongoing performance in the ordinary course of its operations.

    These non-GAAP measures may be different from non-GAAP measures used by other companies.  In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.  The Company believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with U.S. GAAP and that these measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.

    As described above, the Company excludes the following items from one or more of its non-GAAP measures when applicable:

    Employee stock-based compensation expense. These expenses consist primarily of expenses for employee stock options and employee restricted stock under ASC 718 (formerly SFAS 123(R)).  The Company excludes employee stock-based compensation expenses from its non-GAAP measures primarily because they are non-cash expenses that the Company does not believe are reflective of ongoing operating results in the period incurred.  Further, as the Company applies ASC 718, it believes that it is useful to investors to understand the impact of the application of ASC 718 on its results of operations.

    Termination of License.  The Company incurred a one-time expense of $5.4 million in the fourth quarter of 2011 related to the acceleration of the remaining amortization of the original up-front license fee related to the Roche license.  The Company excludes this item because it is one-time and non-cash in nature and not reflective of ongoing operating results in the period incurred.

    Amortization of purchased intangible assets.  The Company incurs amortization of purchased intangible assets in connection with acquisitions.  The Company excludes these items because these expenses are not reflective of ongoing operating results in the period incurred.  These amounts arise from the Company's prior acquisitions and have no direct correlation to the operation of the Company's business.

    Forward-Looking StatementsThis press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to potential growth, future revenues and future net income/loss, including on a non-GAAP basis, and test menu expansion. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our success in increasing direct sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; variability in systems placements and reagent pull-through in the Company's HBDC program; unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.

    All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.FINANCIAL TABLES FOLLOWCEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)Three Months Ended December 31, Years Ended December 31, 2011201020112010Revenues:System sales

    46,416Reagent and disposable sales

    56,57642,969203,576160,460Total product sales

    76,94756,169265,524206,876Other revenues

    3,1672,55712,0515,592Total revenues

    80,11458,726277,575212,468Costs and operating expenses:Cost of product sales

    38,63226,570122,840105,135Collaboration profit sharing

    1,5821,0934,8636,806Research and development

    16,65011,66659,36242,503Sales and marketing

    14,49010,62650,69138,840General and administrative

    10,1536,93236,00424,528Total costs and operating expenses

    81,50756,887273,760217,812Income (loss) from operations

    (1,393)1,8393,815(5,344)Other expense, net

    (506)(346)(1,143)(992)Income (loss) before income taxes

    (1,899)1,4932,672(6,336)Benefit from (provision for) income taxes

    250(148)(45)419Net income (loss)

    (5,917)Basic net income (loss) per share

    (0.10)Diluted net income (loss) per share

    (0.10)Shares used in computing basic net income (loss) per share

    64,11360,41362,73559,712Shares used in computing diluted net income (loss) per share

    64,11363,37266,75059,712CEPHEIDCONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS(in thousands)December 31, 2011December 31, 2010ASSETSCurrent assets:Cash and cash equivalents

    79,538Accounts receivable, net


    62,23937,598Prepaid expenses and other current assets

    5,2454,138Total current assets

    217,867149,284Property and equipment, net

    35,83327,438Other non-current assets

    730607Intangible assets, net


    18,44518,594Total assets

    220,611LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable

    21,957Accrued compensation

    17,92812,594Accrued royalties

    8,3577,994Accrued and other liabilities

    3,0861,288Current portion of deferred revenue

    8,1768,207Current portion of notes payable

    -1,679Total current liabilities

    69,71453,719Long-term portion of deferred revenue

    2,0034,057Notes payable, less current portion

    -4,991Other liabilities

    3,1204,182Total liabilities

    74,83766,949Shareholders' equity:Common stock

    324,211288,387Additional paid-in capital

    93,14472,731Accumulated other comprehensive income

    33726Accumulated deficit

    (205,555)(208,182)Total shareholders' equity

    211,833153,662Total liabilities and shareholders' equity

    220,611CEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS(in thousands)Years Ended December 31,20112010Cash flows from operating activities:Net income (loss)

    (5,917)Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization of property and equipment

    10,2989,326Amortization of intangible assets

    6,5236,966Amortization of terminated patent license

    5,372-Stock-based compensation related to employees and consulting services rendered

    19,76816,615Write-offs of other intangible assets acquired in acquisitions

    -271Unrealized gain on auction rate securities

    -(1,714)Unrealized loss on put option

    -1,844Deferred rent

    1885Changes in operating assets and liabilities:Accounts receivable


    (23,982)124Prepaid expenses and other current assets

    (237)(1,426)Other non-current assets

    (122)(113)Accounts payable and other current liabilities

    11,347(5,112)Accrued compensation

    5,3343,726Deferred revenue

    (2,084)7,062Net cash provided by operating activities

    27,03227,343Cash flows from investing activities:Capital expenditures

    (18,942)(13,047)Acquisition of leasehold improvements

    -125Payments for technology licenses

    (1,655)(1,000)Cost of acquisitions, net

    (296)(1,300)Proceeds from the sales of short-term investments

    -24,800Proceeds from the sale of fixed assets

    20138Net cash provided by (used in) investing activities

    (20,873)9,716Cash flows from financing activities:Net proceeds from the issuance of common shares and exercise of stock options

    35,85715,334Proceeds from notes payable

    -6,448Principal payment of bank borrowing

    -(14,618)Principal payment of notes payable

    (6,669)(618)Net cash provided by financing activities

    29,1886,546Effect of exchange rate change on cash

    123147Net increase in cash and cash equivalents

    35,47043,752Cash and cash equivalents at beginning of period

    79,53835,786Cash and cash equivalents at end of period

    79,538CEPHEIDRECONCILIATION OF GAAP TO NON-GAAP MEASURES (UNAUDITED)(in thousands, except per share data)Three Months Ended

    December 31,Years Ended
    December 31,2011201020112010Cost of product sales$
    5,135  Stock compensation expense(443)(687)(1

    SOURCE Cepheid
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Cepheid Welcomes Senior Vice President of Human Resources
    2. Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain
    3. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
    4. Cepheid to Webcast Upcoming Financial Presentations
    5. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
    6. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
    7. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
    8. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
    9. Cepheid Reports 2009 First Quarter Results
    10. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
    11. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
    Post Your Comments:
    (Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier ... that it has been selected by The Michael J. ... cell lines to academic, pharmaceutical, and biotechnology organizations committed ... the United States , and more ... the United States , and more ...
    (Date:10/8/2015)... Texas , Oct. 8, 2015 The 2015 ... of The University of Texas at Dallas. Aziz Sancar ... UT Dallas in 1977, is one of ... how cells continuously monitor and repair damaged DNA on a molecular ... in molecular and cell biology from UT Dallas ...
    (Date:10/8/2015)... ST. LOUIS , Oct. 8, 2015 /PRNewswire/ ... that the Cerilliant ® brand within its ... its new bile acid reference standards product line ... the most routinely tested bile acids and their ... materials (CRMs) consist of lithocholic acid, taurocholic acid ...
    (Date:10/7/2015)... , Oct. 7, 2015 Boston Scientific ... start of the Boston Scientific Connected Patient Challenge ... in the use of remote patient monitoring to enhance ... and entrepreneurs can submit their ideas and collaborate on ... ). Cambridge, MA ...
    Breaking Biology Technology:
    ... 2011 At the White House today, President Barack ... U.S. recipients of the 2010 Kavli Prizes to recognize ... for which the Prizes are awarded -- astrophysics, nanoscience ... Joined by the President,s science advisor, John ...
    ... Kingdom, June 6, 2011 Oxford BioMedicaplc ... gene therapy company, today announces that it has signed ... biotechnology company specialising in the development of engineered antibody ... engineer an in vivo diagnostic imaging agent ...
    ... Biosciences, a leading innovator in protein diagnostics, announces ... allows researchers to cost effectively accelerate their research ... Avantra,s proven QPDx™ BioChip platform. The QPDx™ platform ... using catalog or custom reagents. Avantra,s ...
    Cached Biology Technology:
    (Date:9/10/2015)... , Sept. 10, 2015 Report Details ... far not quite delivered upon previous expectations of revenues, ... be the breakthrough year in which wearables begin to ... expected. One of the main reasons is the entrance ... not only the SmartWatches market, but the overall size ...
    (Date:9/8/2015)... 8, 2015   TREW Marketing and ... Smart Marketing for Engineers TM : Content and ... reveals insightful findings about engineers, preferences for online content ... engineers most value and trust, and where they look ... technical audiences grapple with how to best implement online ...
    (Date:9/2/2015)... September 2, 2015 ... implied in a system which uses identical human ... iris, vein, DNA and finger print. Increasing number ... develop such system which provides high level of ... Patterns and tokens are vulnerable to attacks. Furthermore, ...
    Breaking Biology News(10 mins):
    ... blueprint of the rock pigeon, unlocking secrets about pigeons, Middle ... how mutations give pigeons traits like feather head crests. ... we know surprisingly little about their genetics," says Michael Shapiro, ... at the University of Utah. In the new study, ...
    ... and NEWTOWN, Pa., Jan. 31, 2013   Shareholder ... the acquisition of BioClinica, Inc. (NASDAQ: BIOC ... solutions to pharmaceutical, biotechnology, and medical device companies. ... On January 30, 2013, BioClinica announced that it had ...
    ... On January 30, 2013 ACS Nano published ... in the division of biomedical engineering at Brigham and ... that utilize nanotechnology to enhance the conductivity of materials ... cardiac patches put medicine a step closer to durable, ...
    Cached Biology News:
    ... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
    ... 5 ml CELLection Dynabeads (4.5 m) coated ... epithelial antigen EpCAM and DNase Releasing Buffer. ... of epithelial tumour cells directly from blood, ... can be enriched from bone marrow. Enriched ...
    Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
    Recombinant Human Erythropoietin (Tissue Culture Grade)...
    Biology Products: